Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV.


Early treatment of infants living with HIV offers a unique population in which to investigate long-term clinical, immunologic, and virologic outcomes and to better characterize how early ART impacts HIV infection over time. The overarching goals of IMPAACT 2028 are to establish long-term follow-up of participants who received early treatment for future interventional cure and/or remission trials and to establish a unique biorepository from which additional scientific questions can be answered. In lower and middle-income settings, where the majority of these trial participants live, the significant mobility of enrolled participants may reduce access for future studies, particularly if they are currently not receiving care at a clinical research site.

The durability of early treatment, the effect of acquired co-infections on reservoir dynamics, the longterm effects of ART and/or bNAbs on a maturing immune system and on the evolution of HIVspecific neutralizing antibodies, cell-mediated immunity, systemic immune activation, inflammation, and the predictive value of biomarkers associated with increased morbidity and mortality in adults are poorly understood in children. It is thus anticipated that IMPAACT 2028 will longitudinally track these participants while simultaneously advancing our understanding of the long-term effects of early ART and/or bNAb initiation through establishing a biorepository to address scientific questions and promote innovation in this field.


  • Dr Faeezah Patel, Principal Investigator
  • Prof Lee Fairlie
  • Dr Mrinmayee Dhar
  • Dr Muneerah Khan
  • Dr Jeanne Coetzee
  • Dr Elizea Horne
  • Othusitse Segal
  • Tiffany Seef

Latest Update

March 2024

For more details about the IMPAACT 2028 Study please email

Click here for further details regarding the IMPAACT 2028 Study.

Research and Policy Briefs


Stay up to date

Get updates on news, resources, events and happenings from Wits RHI.